Results 11 to 20 of about 1,741 (166)

Real-world evidence of tezepelumab for severe asthma: a retrospective multicentre cohort [PDF]

ERJ Open Research
Background Tezepelumab, a monoclonal antibody targeting thymic stromal lymphopoietin, has demonstrated efficacy for severe asthma in clinical trials, but real-world evidence remains limited.
Jasmin Khateeb, Mordechai R. Kramer, Ophir Freund, Reem Mhameed, Eviatar Naamany, Aviv Kupershmidt, Gal Elkayam, Anna Breslavsky, Dror Rosengarten, Yaniv Dotan, Ori Wand, Amir Bar-Shai   +11 more
doaj   +2 more sources

Key role of thymic stromal lymphopoietin as a molecular target for biologic treatment of severe asthma [PDF]

Frontiers in Allergy
Thymic stromal lymphopoietin (TSLP) is an alarmin mainly released by airway epithelial cells injured by many environmental noxious agents such as aeroallergens, respiratory viruses, bacteria, airborne pollutants and cigarette smoking.
Corrado Pelaia, James Melhorn, Giovanni Paoletti, Giovanni Paoletti, Remo Poto, Remo Poto, Angelantonio Maglio, Claudia Crimi, Alessandro Vatrella, Giorgio Walter Canonica, Giorgio Walter Canonica, Girolamo Pelaia   +11 more
doaj   +2 more sources

Tezepelumab as an Emerging Therapeutic Option for the Treatment of Severe Asthma: Evidence to Date

Drug Design, Development and Therapy, 2021
Zachariah L Dorey-Stein, Kartik V Shenoy Department of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USACorrespondence: Zachariah L Dorey-SteinDepartment of Thoracic Medicine and Surgery, Lewis Katz ...
Zachariah Dorey-Stein
exaly   +2 more sources

Which Is the Best Biologic for Nasal Polyps: An Updated Network Meta‐Analysis [PDF]

Clinical and Translational Allergy
Background Direct comparative efficacy data for biologics in chronic rhinosinusitis with nasal polyps (CRSwNP) remain limited, particularly for novel agents like tezepelumab, underscoring the need to identify optimal therapies for precision management ...
Xi Xu, Jinting Lin, Minting Luo, Qingwu Wu   +3 more
doaj   +2 more sources

Efficacy and Potential Positioning of Tezepelumab in the Treatment of Severe Asthma

Open Respiratory Archives, 2023
The excellent results for monoclonal antibodies in the treatment of severe uncontrolled asthma (SUCA) represent a milestone in current treatment of asthmatic disorders.
Vicente Plaza, Conxa Cañete, Christian Domingo, Carlos Martínez Rivera, Xavier Muñoz   +4 more
doaj   +4 more sources

Case Report: Sequential use of tezepelumab and mepolizumab for eosinophilic otitis media in EGPA: a steroid-sparing strategy [PDF]

Frontiers in Allergy
Even in eosinophilic granulomatosis with polyangiitis (EGPA), not all manifestations of eosinophilic inflammation respond equally to anti–interleukin-5 (IL-5) therapy.
Osamu Matsuno, Masahiro Kawamoto, Tansri Wibowo, Yutaka Ishida, Atsuhsi Ogata   +4 more
doaj   +2 more sources

COPD 2.0: Bronchodilators, biologics and beyond - A systematic review [PDF]

Lung India
Chronic obstructive pulmonary disease (COPD) is a progressive respiratory disorder characterized by persistent airflow limitation and chronic inflammation. Conventional bronchodilators have been the mainstay of therapy; however, their efficacy in certain
Huda Shamim, Anil Kumar Singh, Rahul Sharma, Rajat Kumar Mishra   +3 more
doaj   +2 more sources

Efficacy and safety of tezepelumab in patients recruited in Japan who participated in the phase 3 NAVIGATOR study

Allergology International, 2023
Background: Tezepelumab, a human monoclonal antibody, blocks the activity of thymic stromal lymphopoietin. In the phase 3 NAVIGATOR study (NCT03347279), tezepelumab reduced exacerbations by 56% compared with placebo in adults and adolescents with severe,
Tamotsu Ishizuka, Andrew Menzies-Gow, Hiroshi Okada, Yasushi Fukushima, Nobuya Hayashi, Gene Colice, Sandhia Ponnarambil, Gillian Hunter, Hiroshi Odajima, Motohiro Ebisawa   +9 more
doaj   +1 more source

Current summary of clinical studies on anti-TSLP antibody, Tezepelumab, in asthma

Allergology International, 2023
Thymic stromal lymphopoietin (TSLP) is an epithelial cell-derived cytokine that plays a vital role in the induction of type 2 inflammation via both innate and acquired immune cascades.
Momoko Kurihara, Hiroki Kabata, Misato Irie, Koichi Fukunaga   +3 more
doaj   +1 more source

DESTINATION: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the long-term safety and tolerability of tezepelumab in adults and adolescents with severe, uncontrolled asthma

Respiratory Research, 2020
Background Tezepelumab is a human monoclonal antibody that blocks the activity of the epithelial cytokine thymic stromal lymphopoietin. The efficacy, safety and oral corticosteroid-sparing potential of tezepelumab are being investigated in two ongoing ...
Andrew Menzies-Gow, Sandhia Ponnarambil, John Downie, Karin Bowen, Åsa Hellqvist, Gene Colice   +5 more
doaj   +1 more source